MannKind (MNKD) is a US-listed Healthcare company in Biotechnology with a market capitalization of
MannKind (MNKD) has a market capitalization of approximately
MannKind runs a net profit margin of -6.6%, a gross margin of 76.0%, and an operating margin of 3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
MannKind reported revenue of
MannKind does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
MannKind carries a debt-to-equity ratio of -7.38x and a current ratio of 1.87x, with a market beta of 1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MannKind (MNKD) the key facts are: market cap
Get MannKind's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.